AllSight
Companies · SLDB · Biological Products, (No Diagnostic Substances)

Solid Biosciences Inc. (SLDB)

Solid Biosciences Inc. (SLDB) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Solid Biosciences Inc. (SLDB) stock — financials & valuation

Key numbers for Solid Biosciences Inc. (SLDB): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 36/100 — a percentile rank of Solid Biosciences Inc.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.

Market cap$775.2M
EV / EBITDA-2.9×
Return on equity-55.4%
ROIC-98.8%
Debt / equity0.0×
Dividend yield0.0%

Is Solid Biosciences Inc. overvalued? P/B looks overvalued vs its 5-year range.

Independent of the events above — derived from Solid Biosciences Inc.’s own financial statements and shown as context, never as advice.

Aug 6, 2026$200M ATM
Solid Biosciences expands ATM to $200M after exhausting prior capacity
Related companies in Biological Products, (No Diagnostic Substances)
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact